Table 3.
Biologic agent | Clinical setting | Mechanism of action | Loss of exclusivity US, year | Loss of exclusivity EU, year |
---|---|---|---|---|
Trastuzumab | HER2-overexpressing breast and gastric cancer | HER2-targeted mAb | 2019 | 2014 |
Rituximab | Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia | CD20-targeted mAb | 2017 | 2014 |
Bevacizumab | Non-small cell lung cancer, colorectal cancer | VEGF-targeted angiogenesis inhibitor | 2019 | 2020 |
Cetuximab | Head and neck cancer, colorectal cancer | EGFR inhibitor (mAb) | 2016 | 2016 |
Abbreviations: mAb, monoclonal antibody; EGFR, epidermal growth factor receptor; US, United States; HER2, human epidermal growth factor 2; EU, European Union; VEGF, vascular endothelial growth factor.